Stock Worth Mentioning: Progenics Pharmaceuticals, Inc. Sets 52-Week High; Strong Momentum for Holders

Stock Worth Mentioning: Progenics Pharmaceuticals, Inc. Sets 52 Week High; Strong Momentum for Holders

The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) hit a new 52-week high and has $12.26 target or 49.00% above today’s $8.23 share price. The 8 months bullish chart indicates low risk for the $584.20 million company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $12.26 price target is reached, the company will be worth $286.26 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 804,652 shares traded hands. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 56.45% since April 19, 2016 and is uptrending. It has outperformed by 52.58% the S&P500.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage

Out of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Friday, August 7 by Needham. The firm earned “Buy” rating on Thursday, August 6 by Brean Capital. On Friday, October 23 the stock rating was upgraded by Jefferies to “Buy”. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”. The stock has “Buy” rating given by Zacks on Friday, August 7.

According to Zacks Investment Research, “Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.”

Insitutional Activity: The institutional sentiment increased to 1.17 in Q2 2016. Its up 0.41, from 0.76 in 2016Q1. The ratio improved, as 25 funds sold all Progenics Pharmaceuticals, Inc. shares owned while 29 reduced positions. 12 funds bought stakes while 29 increased positions. They now own 58.35 million shares or 1.82% less from 59.43 million shares in 2016Q1.
Morgan Stanley accumulated 23,652 shares or 0% of the stock. Northern Tru Corp has 0% invested in the company for 808,834 shares. Creative Planning owns 3,000 shares or 0% of their US portfolio. Vanguard Grp holds 0% or 2.74M shares in its portfolio. Voya Inv Mgmt Lc owns 31,737 shares or 0% of their US portfolio. California State Teachers Retirement has 0% invested in the company for 145,011 shares. Blackrock Advisors Limited Liability has 95,889 shares for 0% of their US portfolio. Principal Financial Gp Inc reported 12,026 shares or 0% of all its holdings. Shinko Asset Comm Ltd has 0% invested in the company for 140,191 shares. Swiss Bank accumulated 115,700 shares or 0% of the stock. The New York-based Clear Harbor Asset Management Lc has invested 0.05% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Credit Suisse Ag reported 83,074 shares or 0% of all its holdings. Broadfin Capital Ltd Liability Corporation holds 8.95 million shares or 3.67% of its portfolio. Strs Ohio has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Tiaa Cref Investment Mngmt Ltd Liability Co last reported 259,972 shares in the company.

More news for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were recently published by: Seekingalpha.com, which released: “Progenics Pharmaceuticals: 25% Upside Left After 60% Move?” on November 20, 2016. Fool.com‘s article titled: “Why Progenics Pharmaceuticals, Inc. Shares Soared Today” and published on July 20, 2016 is yet another important article.

PGNX Company Profile

Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment